莫利司他治疗日本透析肾性贫血患者的III期研究
MIYABI血液透析维持研究是一项52周随机双盲双模拟III期试验,在229例日本血液透析并接受促红细胞生成素治疗的肾性贫血患者中比较莫利司他与达依泊汀α。主要终点为评价期(第33-36周)平均血红蛋白水平及其较基线变化,莫利司他不劣于达依泊汀α,两组平均Hb均维持在目标范围内。
要点
- 莫利司他(起始75mg/日)在透析患者中维持Hb不劣于达依泊汀α。
- 评价期平均Hb:莫利司他10.63 g/dl,达依泊汀α10.77 g/dl,均在目标范围。
- 两组多数患者发生至少1例治疗中出现的不良事件。
核心结论
- 莫利司他在既往接受促红细胞生成素治疗的透析患者中维持Hb水平,且不劣于达依泊汀α。
研究设计与样本
- 52周随机双盲双模拟III期研究,纳入229例日本血液透析并接受促红细胞生成素治疗的肾性贫血患者。
- 莫利司他组153例,达依泊汀α组76例;莫利司他起始剂量75 mg/日,两组均滴定维持Hb≥10.0且<12.0 g/dl。
主要发现
- 评价期(第33-36周)平均Hb:莫利司他10.63 g/dl(95%CI 10.42-10.84),达依泊汀α10.77 g/dl(95%CI 10.59-10.95)。
- 评价期平均Hb较基线最小二乘均值变化:莫利司他-0.14 g/dl(95%CI -0.37至0.09),达依泊汀α-0.07 g/dl(95%CI -0.30至0.16)。
- 两组最小二乘均值差(莫利司他-达依泊汀α)为-0.13 g/dl(95%CI -0.46至0.19),基于1.0 g/dl的非劣效界值。
- 多数受试者发生至少1例治疗中出现的不良事件。
关键数值与推荐
- Hb目标范围:≥10.0且<12.0 g/dl。
- 非劣效界值:1.0 g/dl。
- 莫利司他起始剂量:75 mg/日。
临床怎么用
- 对于血液透析并接受促红细胞生成素治疗的肾性贫血患者,莫利司他可作为维持Hb的替代选择。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Molidustat, a hypoxia-inducible factor prolyl hydroxylase inhibitor for renal anemia treatment, was evaluated in 5 phase 3 studies (MIYABI program). We report the results of the MIYABI hemodialysis-maintenance study. METHODS: This 52-week, randomized, double-blinded, double-dummy study compared the efficacy and safety of molidustat and darbepoetin in Japanese patients receiving hemodialysis and erythropoiesis-stimulating agents. Molidustat (starting dose: 75 mg/day) and darbepoetin were titrated to maintain hemoglobin (Hb) levels in the target range (≥10.0 and <12.0 g/dl). Primary outcomes were mean Hb level during the evaluation period (weeks 33-36) and its change from baseline. Safety outcomes included adverse events. RESULTS: Overall, 229 patients were randomized (molidustat, n = 153; darbepoetin, n = 76). Baseline characteristics were well balanced. Mean baseline Hb level was 10.8 g/dl. Mean (95% confidence interval [CI]) for mean Hb levels during the evaluation period were within the target range in both groups (molidustat: 10.63 [10.42-10.84] g/dl; darbepoetin: 10.77 [10.59-10.95] g/dl). Least-squares mean (95% CI) change in mean Hb level during the evaluation period from baseline was -0.14 (-0.37 to 0.09) g/dl for molidustat and -0.07 (-0.30 to 0.16) g/dl for darbepoetin; molidustat was noninferior to darbepoetin (least-squares mean difference [95% CI] [molidustat-darbepoetin]: -0.13 [-0.46 to 0.19] g/dl), based on a noninferiority margin of 1.0 g/dl. In line with published literature, and as expected in this patient population, most participants had ≥1 treatment-emergent adverse event. CONCLUSION: Molidustat maintained Hb levels throughout the trial in patients receiving dialysis and previously treated with erythropoiesis-stimulating agents, and was noninferior to darbepoetin.
引用
- Akizawa T, Yamada T, Nobori K, et al. Molidustat for Japanese Patients With Renal Anemia Receiving Dialysis. Kidney Int Rep. 2021. PMID: 34622100. doi:10.1016/j.ekir.2021.07.015
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。